Home/Filings/4/0001725160-25-000037
4//SEC Filing

Bruns Ingmar 4

Accession 0001725160-25-000037

CIK 0001725160other

Filed

Feb 4, 7:00 PM ET

Accepted

Feb 5, 6:30 PM ET

Size

7.4 KB

Accession

0001725160-25-000037

Insider Transaction Report

Form 4
Period: 2025-02-03
Bruns Ingmar
Chief Medical Officer
Transactions
  • Award

    Stock Option (Right to Buy)

    2025-02-03+16,62916,629 total
    Exercise: $1.68Exp: 2035-02-02Common Stock (16,629 underlying)
  • Award

    Common Stock

    2025-02-03+16,62916,629 total
Footnotes (2)
  • [F1]Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a two year period following the grant date, subject to the Reporting Person's continued service with the Issuer.
  • [F2]The options will vest over four years in substantially equal monthly installments until the options are fully vested, subject to the Reporting Person's continued service with the Issuer.

Issuer

Zentalis Pharmaceuticals, Inc.

CIK 0001725160

Entity typeother

Related Parties

1
  • filerCIK 0001838041

Filing Metadata

Form type
4
Filed
Feb 4, 7:00 PM ET
Accepted
Feb 5, 6:30 PM ET
Size
7.4 KB